Small molecule · Modulator of GABA-A receptor · developed by Sage Therap Supernus
Brexanolone is a neuroactive steroid that acts as a positive allosteric modulator of GABA-A receptors.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Dec 31, 2024). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05059600 | Phase 4 | Postpartum Depression | Completed | SUPN |
| NCT07822321 | Phase 3 | Depression, Postpartum | Recruiting | LPCN |
| NCT03665038 | Phase 3 | Post Partum Depression | Completed | SUPN |
| NCT02942004 | Phase 3 | Postpartum Depression | Completed | SUPN |
| NCT02477618 | Phase 3 | Super-Refractory Status Epilepticus | Completed | SUPN |
| NCT03924492 | N/A | Postpartum Depression | Approved for marketing | SUPN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Depression, PostpartumPeripartum DepressionPost-Natal DepressionPost-partum DepressionPostnatal DepressionPostpartum Depression (PPD)Postpartum DepressionSuper-Refractory Status Epilepticus
Updated Nov 1, 2026. Something wrong or missing? Report it on the SUPN page.
See SUPN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SUPN catalysts and pipeline →